Etodolac

CHEMBL622 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
287.4 g/mol
LogP
2.8
Phase
4

This NSAID reduces pain and inflammation by blocking COX enzymes that produce inflammatory prostaglandins throughout the body. It is used to treat arthritis pain, acute pain, and other inflammatory conditions.

Masse moléculaire

287,3500 g/mol

LogP

2,80

TPSA

62,30 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3

InChI

InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)

Molecular Formula

C17H21NO3

HBD / HBA

2 / 3

Liaisons Rotatives

4

Atomes Lourds

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This NSAID reduces pain and inflammation by blocking COX enzymes that produce inflammatory prostaglandins throughout the body. It is used to treat arthritis pain, acute pain, and other inflammatory conditions.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Etodolac is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL622. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3308. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.